These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 28461320)

  • 21. Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor.
    Furiga A; Lajoie B; El Hage S; Baziard G; Roques C
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1676-86. PubMed ID: 26711774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain.
    Cirioni O; Ghiselli R; Silvestri C; Kamysz W; Orlando F; Mocchegiani F; Di Matteo F; Riva A; Lukasiak J; Scalise G; Saba V; Giacometti A
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2005-10. PubMed ID: 17403995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro efficacy of various antibiotic combinations against Pseudomonas aeruginosa isolates.
    Nazli E; Zer Y; Eksi F
    J Int Med Res; 2015 Apr; 43(2):217-25. PubMed ID: 25547417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa.
    Di X; Wang R; Liu B; Zhang X; Ni W; Wang J; Liang B; Cai Y; Liu Y
    J Antibiot (Tokyo); 2015 Sep; 68(9):551-5. PubMed ID: 25805069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection.
    Wang Y; Li C; Wang J; Bai N; Zhang H; Chi Y; Cai Y
    Microbiol Spectr; 2022 Oct; 10(5):e0146822. PubMed ID: 36102678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breaking the Vicious Cycle of Antibiotic Killing and Regrowth of Biofilm-Residing
    Müsken M; Pawar V; Schwebs T; Bähre H; Felgner S; Weiss S; Häussler S
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imipenem/Cilastatin/Relebactam Alone and in Combination against
    Chen IH; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 33139283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro efficacy of colistin against multi-drug resistant Pseudomonas aeruginosa by minimum inhibitory concentration.
    Gill MM; Rao JU; Kaleem F; Hassan A; Khalid A; Anjum R
    Pak J Pharm Sci; 2013 Jan; 26(1):7-10. PubMed ID: 23261721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones.
    Montero MM; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Segura C; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    J Glob Antimicrob Resist; 2019 Sep; 18():37-44. PubMed ID: 31154007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
    Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
    J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Vivo and in Vitro activity of colistin-conjugated bimetallic silver-copper oxide nanoparticles against Pandrug-resistant Pseudomonas aeruginosa.
    Abdul Hak A; Zedan HH; El-Mahallawy HA; El-Sayyad GS; Zafer MM
    BMC Microbiol; 2024 Jun; 24(1):213. PubMed ID: 38886632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of colistin dosing regimen for cystic fibrosis patients with chronic Pseudomonas aeruginosa biofilm lung infections.
    Hengzhuang W; Green K; Pressler T; Skov M; Katzenstein TL; Wu X; Høiby N
    Pediatr Pulmonol; 2019 May; 54(5):575-580. PubMed ID: 30803159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro synergistic activity of colistin and ceftazidime or ciprofloxacin against multidrug-resistant clinical strains of Pseudomonas aeruginosa.
    D'Souza BB; Padmaraj SR; Rekha PD; Tellis RC; Prabhu S; Pothen P
    Microb Drug Resist; 2014 Dec; 20(6):550-4. PubMed ID: 25055029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nutrient dispersion enhances conventional antibiotic activity against Pseudomonas aeruginosa biofilms.
    Sommerfeld Ross S; Fiegel J
    Int J Antimicrob Agents; 2012 Aug; 40(2):177-81. PubMed ID: 22727773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients.
    Sans-Serramitjana E; Fusté E; Martínez-Garriga B; Merlos A; Pastor M; Pedraz JL; Esquisabel A; Bachiller D; Vinuesa T; Viñas M
    J Cyst Fibros; 2016 Sep; 15(5):611-8. PubMed ID: 26708265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro and in vivo Pharmacodynamics of Colistin and Aztreonam Alone and in Combination against Multidrug-Resistant Pseudomonas aeruginosa.
    Yamagishi Y; Hagihara M; Kato H; Hirai J; Nishiyama N; Koizumi Y; Sakanashi D; Suematsu H; Nakai H; Mikamo H
    Chemotherapy; 2017; 62(2):105-110. PubMed ID: 27788502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of nonclonal Pseudomonas aeruginosa isolates with reduced colistin susceptibility in Korea.
    Lee JY; Song JH; Ko KS
    Microb Drug Resist; 2011 Jun; 17(2):299-304. PubMed ID: 21381965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of
    Valzano F; Boncompagni SR; Micieli M; Di Maggio T; Di Pilato V; Colombini L; Santoro F; Pozzi G; Rossolini GM; Pallecchi L
    Microbiol Spectr; 2022 Aug; 10(4):e0100622. PubMed ID: 35735984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic effects of pomegranate and rosemary extracts in combination with antibiotics against antibiotic resistance and biofilm formation of Pseudomonas aeruginosa.
    Abu El-Wafa WM; Ahmed RH; Ramadan MA
    Braz J Microbiol; 2020 Sep; 51(3):1079-1092. PubMed ID: 32394240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli.
    Barb AW; McClerren AL; Snehelatha K; Reynolds CM; Zhou P; Raetz CR
    Biochemistry; 2007 Mar; 46(12):3793-802. PubMed ID: 17335290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.